Lieber Jonathan I — SEC insider filings

SEC reporting owner CIK 1350090. 20 insider filings on record with FilingPulse; latest filed 2026-11-03.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2020-12-04 to 2026-11-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Rallybio Corp (RLYB)Chief Financial Officer101 leg · 5,000 sh · $26,0502 legs · 1,388 sh · $13,60015
Decoy Therapeutics Inc. (DCOY)Director61 leg · 37,500 sh · $7,016—5
APPLIED GENETIC TECHNOLOGIES CORP (AGTC)Chief Financial Officer3——4
Bambusa Therapeutics, Inc. (BBTX)Chief Financial Officer1———

Insider filings — Lieber Jonathan I

FiledFormIssuerReported transactionsSource
2026-11-034Rallybio Corp (RLYB)Option exercise (M): 7,124 @ $14.88 · Option exercise (M): 7,124 (derivative) @ $0EDGAR
2026-11-024Rallybio Corp (RLYB)Option exercise (M): 7,875 @ $14.88 · Option exercise (M): 13,589 @ $6.08 · Option exercise (M): 7,875 (derivative) @ $0 · Option exercise (M): 13,589 (derivative) @ $0EDGAR
2026-10-293Bambusa Therapeutics, Inc. (BBTX)Holdings only — no transactions reportedEDGAR
2026-10-284Rallybio Corp (RLYB)Grant/award (A): 2,500 @ $0 · Sale (S): 599 @ $16.04EDGAR
2026-10-134Rallybio Corp (RLYB)Option exercise (M): 3,910 @ $6.08 · Option exercise (M): 3,910 (derivative) @ $0EDGAR
2026-10-014Rallybio Corp (RLYB)Option exercise (M): 5,000 @ $6.08 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2026-09-024Decoy Therapeutics Inc. (DCOY)Grant/award (A): 2,000 @ $0EDGAR
2026-02-234Rallybio Corp (RLYB)Grant/award (A): 2,500 @ $0 · Sale (S): 789 @ $5.06EDGAR
2025-02-194Rallybio Corp (RLYB)Grant/award (A): 180,000 (derivative) @ $0EDGAR
2024-02-224Salarius Pharmaceuticals, Inc. (SLRX)Grant/award (A): 20,500 (derivative) @ $0EDGAR
2024-02-164Rallybio Corp (RLYB)Grant/award (A): 120,000 (derivative) @ $0EDGAR
2023-03-164Rallybio Corp (RLYB)Purchase (P): 5,000 @ $5.21EDGAR
2023-02-014Rallybio Corp (RLYB)Grant/award (A): 240,000 (derivative) @ $0EDGAR
2023-01-054Salarius Pharmaceuticals, Inc. (SLRX)Grant/award (A): 1,440 @ $0EDGAR
2022-12-014APPLIED GENETIC TECHNOLOGIES CORP (AGTC)Disposition to issuer (D): 202,000 (derivative) · Disposition to issuer (D): 154,700 (derivative)EDGAR
2022-08-244APPLIED GENETIC TECHNOLOGIES CORP (AGTC)Grant/award (A): 154,700 (derivative) @ $0EDGAR
2022-06-084Salarius Pharmaceuticals, Inc. (SLRX)Purchase (P): 37,500 @ $0.19EDGAR
2022-01-214Salarius Pharmaceuticals, Inc. (SLRX)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2021-09-214APPLIED GENETIC TECHNOLOGIES CORP (AGTC)Grant/award (A): 202,000 (derivative) @ $0EDGAR
2020-12-044Salarius Pharmaceuticals, Inc. (SLRX)Grant/award (A): 30,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1350090 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs